Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi's sarcoma. A double blind, randomized clinical trial

Oral Oncology

Volumn 38, Issue 5, 2002, Pages 460-467

  Ramirez Amador V ^a,f   Esquivel Pedraza, L ^b   Lozada Nur, F ^c   De La Rosa Garcia E ^a   Volkow Fernandez P ^d   Suchil Bernal L ^d   Mohar, A ^d,e  

^a DEPARTAMENTO DE SISTEMAS BIOLÓGICOS   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f NONE   (Mexico)

Author keywords

AIDS; Kaposi's sarcoma; Oral; Sodium tetradecyl sulfate; Vinblastine

Indexed keywords

TETRADECYL SULFATE SODIUM; VINBLASTINE; VINBLASTINE SULFATE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOXICITY; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOUBLE-BLIND METHOD; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; MOUTH NEOPLASMS; SARCOMA, KAPOSI; SCLEROSING SOLUTIONS; SODIUM TETRADECYL SULFATE; TREATMENT OUTCOME; VINBLASTINE;

EID: 0036318054     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(01)00100-2     Document Type: Article

References (37)

1. Overview of the epidemiology of immunodeficiency-associated cancers
2. The epidemiology of acquired immunodeficiency syndrome malignancies
3. Human herpes virus 8: A new virus discloses its face
4. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
5. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases
6. Sexual transmission and the natural history of human herpesvirus 8 infection
7. Kaposi's sarcoma-associated herpesvirus-like DNA sequences (KSHV/HHV-8) in oral AIDS-Kaposi's sarcoma. A PCR and clinicopathological study
8. Human herpesvirus 8 and oral health care: An update
9. Mucosal shedding of human herpesvirus 8 in men
10. Shedding of cytomegalovirus and herpesviruses 6, 7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls
11. Presence of human herpesvirus 8 variants in the oral tissues of human immunodeficiency virus-infected persons
12. Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus
13. The epidemiology of AIDS-related neoplasms
14. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
15. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy
16. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997
17. Oral findings in Mexican AIDS patients with cancer
18. Kaposi's sarcoma in AIDS Mexican patients
19. Kaposi's sarcoma of the oral cavity: A study of 134 patients with a review of the pathogenesis, epidemiology,clinical aspects, and treatment
20. Overview of the management of AIDS-related Kaposi's sarcoma
21. Management of oral Kaposi's sarcoma and a proposal for clinical staging
22. Treatment of Kaposi's sarcoma [editorial review]
23. A case series of acquired immunodeficiency syndrome patients with initial neoplastic diagnoses of intraoral Kaposi's sarcoma
24. Anticancer drugs derived from plants
25. Symptomatic hemangiomas and venous malformations in infants, children, and young adults: Treatment with percutaneous injection of sodium tetradecyl sulfate
26. Eleven-year survey of safety and efficacy of endoscopic injection sclerotherapy using 2% sodium tertadecyl sulfate and constrast medium
27. Intralesional vinblastine injections for the treatment of oral Kaposi's sarcoma: Report of 10 patients with 2-year follow-up
28. Role of intralesional vinblastine administration in treatment of intraoral Kaposi's sarcoma in AIDS
29. Treatment of oral Kaposi sarcoma with intralesional vinblastine
30. Treating Kaposi's sarcoma in the HIV-infected patient
31. Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine
32. Intralesional vinblastine for oral Kaposi sarcoma in HIV infection
33. Sclerotherapy for the treatment of nodular intraoral Kaposi's sarcoma in patients with AIDS
34. Treatment of oral Kaposi's sarcoma with a sclerosing agent in AIDS patients. A preliminary study
35. Classification and diagnostic criteria for oral lesions in HIV infection
36. Kaposi's sarcoma
37. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection